Hydrocortisone - Diurnal

Drug Profile

Hydrocortisone - Diurnal

Alternative Names: Chronocort; Hydrocortisone extended release - Diurnal; Infacort

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Diurnal
  • Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital adrenal hyperplasia; Adrenal insufficiency
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Adrenal insufficiency; Congenital adrenal hyperplasia

Most Recent Events

  • 20 May 2016 Diurnal completes a phase III trial in Adrenal insufficiency in Germany (EudraCT2014-002265-30)
  • 01 Feb 2016 Phase-III clinical trials in Congenital adrenal hyperplasia in USA (PO) (NCT02716818)
  • 20 Oct 2015 Diurnal initiates the follow-up phase III Infacort004 trial in Adrenal insufficiency (In children, In infants, In neonates) in Germany (PO) (EudraCT2015-000458-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top